Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | EVP & CHRO | March 10, 2023 | March 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date March 10, 2023 · Filed March 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,446 |
Ending reported balance
After 2023-03-13 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2023-03-10 · Grant · Acquired 2,532 · Balance 21,137 Row 2 · 2023-03-11 · Tax withholding · Disposed 483 · Balance 20,654 Row 3 · 2023-03-11 · Tax withholding · Disposed 277 · Balance 20,377 Row 4 · 2023-03-12 · Tax withholding · Disposed 448 · Balance 19,929 Row 5 · 2023-03-12 · Tax withholding · Disposed 269 · Balance 19,660 Row 6 · 2023-03-12 · Tax withholding · Disposed 255 · Balance 19,405 Row 7 · 2023-03-13 · Tax withholding · Disposed 659 · Balance 18,746 Row 8 · 2023-03-13 · Tax withholding · Disposed 300 · Balance 18,446 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.87 · Expires 2031-03-10 | Direct | 6,201 |
Reported balance
After 2023-03-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-03-10 · Grant · Acquired 6,201 · Balance 6,201 F1: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/10/2023. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/10/2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Catalent, Inc.
Report date December 18, 2024 · Filed December 18, 2024
Section 16 reporting ended · disclosed 2024-12-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-12-18 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-12-18 · Disposition to issuer · Disposed 39,366 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: Includes restricted stock units ("RSUs"). F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration"). F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms. Row 2 · 2024-12-18 · Grant · Acquired 12,032 · Balance 12,032 F5: At the Effective Time, each performance stock unit ("PSU"), whether or not vested, outstanding immediately prior to the Effective Time vested based on the greater of (i) the target level of performance or (ii) the actual level of performance as of the Effective Time as determined by the Issuer's board of directors or a committee thereof in its reasonable discretion (other than all then-outstanding awards of PSUs for which the applicable performance period has been completed and the actual level of performance has been certified, in each case, prior to the Effective Time, which vested in accordance with the actual level of performance). PSUs granted with respect to the fiscal 2023-2025 performance period vested at the target level of performance and PSUs granted with respect to the fiscal 2024-2026 performance period vested at 150%, the actual level of performance as of the Effective Time. Row 3 · 2024-12-18 · Disposition to issuer · Disposed 12,032 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F6: At the Effective Time, each outstanding PSU was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the PSU as determined in accordance with the Merger Agreement multiplied by (ii) the Merger Consideration. |
| Options to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $46.51 · Expires 2033-08-01 | Direct | 0 |
Reported balance
After 2024-12-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-12-18 · Disposition to issuer · Disposed 14,225 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F7: At the Effective Time, each stock option, whether or not vested, outstanding immediately before the Effective Time vested (if unvested) and was cancelled and entitled the holder of such option to receive an amount in cash, without interest, equal to the product of (i) the excess, if any, of (A) the Merger Consideration over (B) the per-share exercise price for such option multiplied by (ii) the total number of shares of Issuer common stock underlying such option. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
F2: Includes restricted stock units ("RSUs").
F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration").
F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms.
F5: At the Effective Time, each performance stock unit ("PSU"), whether or not vested, outstanding immediately prior to the Effective Time vested based on the greater of (i) the target level of performance or (ii) the actual level of performance as of the Effective Time as determined by the Issuer's board of directors or a committee thereof in its reasonable discretion (other than all then-outstanding awards of PSUs for which the applicable performance period has been completed and the actual level of performance has been certified, in each case, prior to the Effective Time, which vested in accordance with the actual level of performance). PSUs granted with respect to the fiscal 2023-2025 performance period vested at the target level of performance and PSUs granted with respect to the fiscal 2024-2026 performance period vested at 150%, the actual level of performance as of the Effective Time.
F6: At the Effective Time, each outstanding PSU was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the PSU as determined in accordance with the Merger Agreement multiplied by (ii) the Merger Consideration.
F7: At the Effective Time, each stock option, whether or not vested, outstanding immediately before the Effective Time vested (if unvested) and was cancelled and entitled the holder of such option to receive an amount in cash, without interest, equal to the product of (i) the excess, if any, of (A) the Merger Consideration over (B) the per-share exercise price for such option multiplied by (ii) the total number of shares of Issuer common stock underlying such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2018 Filed Mar 15, 2018 20:23 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 102 | $56.23 | $5,735.46 |
DisclosureSEC source: 0001209191-18-019840 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,305 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:23 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019840 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,407 Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:28 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011353 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,222 F2 · shares: On February 15, 2018, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2017, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 33% of the shares will vest on March 13, 2018 at 150% target, the first anniversary of the grant date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:28 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011353 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,835 F1 · shares: On February 15, 2018, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2017, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2018 at 150% target, the second anniversary of the grant date. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 262 | $53.41 | $13,993.42 |
DisclosureSEC source: 0001209191-18-007425 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,665 Read SEC document |
| March 14, 2017 Filed Mar 15, 2017 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 95 | $43.03 | $4,087.85 |
DisclosureSEC source: 0001209191-17-020782 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,927 Read SEC document |
| March 14, 2017 Filed Mar 15, 2017 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 356 | $43.03 | $15,318.68 |
DisclosureSEC source: 0001209191-17-020782 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,022 Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,337 | $0.00 Strike: $43.68 | $0.00 |
DisclosureSEC source: 0001209191-17-020782 · doc4.xml · derivative · entry 4 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,337 Underlying: Common Stock · 4,337 shares Expires 2025-03-13 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/13/2017. Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020782 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,378 Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 21:31 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-012118 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,256 F1 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2017 at 150% target, the first anniversary of the grant date. F2 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date and one additional unit of unvested performance based restricted stock ("PSU") for each PSU owned as of that date, as reflected in the totals listed on this Form 4. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:04 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 286 | $42.09 | $12,037.74 |
DisclosureSEC source: 0001209191-17-007554 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,086 F1 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date, as reflected in the totals listed on this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.